Literature DB >> 27860441

Effects of human chorionic gonadotropin on testicular interstitial tissues in men with non-obstructive azoospermia.

S Oka1, K Shiraishi1, H Matsuyama1.   

Abstract

Non-obstructive azoospermia is a severe condition because spermatogenesis per se is disrupted. Although microdissection testicular sperm extraction is the standard therapy for non-obstructive azoospermia, sperm retrieval is unsuccessful in approximately 50% of patients. For these patients, we conducted human chorionic gonadotropin-based salvage hormonal therapy, and sperm retrieval was possible in 10-20% of patients. The objectives of this study were to assess the changes in interstitial lesions in patients with non-obstructive azoospermia and to evaluate the effects of human chorionic gonadotropin on these tissues. Testicular biopsy specimens were obtained from 10 non-obstructive azoospermia patients who failed to obtain spermatozoa and from 10 obstructive azoospermia patients. All non-obstructive azoospermia patients received salvage hormonal therapy after microdissection testicular sperm extraction. Hematoxylin and eosin (H.E.) staining and immunohistochemical staining for steroidogenic acute regulatory protein antibody, the Leydig cell marker, and TE-7 antibody, the fibroblast marker, as well as picrosirius red staining to detect collagen fibers, were performed. We measured interstitial lesions, as Leydig cell area and the other area, with ImageJ software. Interstitial area, excluding Leydig cells, increased up to 12.5% in non-obstructive azoospermia compared with 1.2% in obstructive azoospermia (p < 0.01), which was mainly because of fibrosis with TE-7-positive fibroblasts. The increase in interstitial lesions was correlated with Johnsen scores. Interstitial area, excluding the Leydig cells, decreased by 29% after salvage hormonal therapy (p < 0.05), indicating improvement of interstitial fibrosis in non-obstructive azoospermia. There were no significant difference in total Leydig cell area and size of each Leydig cells between obstructive azoospermia and non-obstructive azoospermia. After the salvage hormonal therapy, a portion of the Leydig cells became hypertrophied and mean diameter of Leydig cell significantly increased (p < 0.01). This study showed anti-fibrotic effects of human chorionic gonadotropin and hypertrophic change of Leydig cells after human chorionic gonadotropin administration.
© 2016 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  Leydig cell; azoospermia; fibroblast; fibrosis; human chorionic gonadotropin; micro-TESE

Mesh:

Substances:

Year:  2016        PMID: 27860441     DOI: 10.1111/andr.12292

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  10 in total

1.  Directing differentiation of human induced pluripotent stem cells toward androgen-producing Leydig cells rather than adrenal cells.

Authors:  Lu Li; Yuchang Li; Chantal Sottas; Martine Culty; Jinjiang Fan; Yiman Hu; Garett Cheung; Héctor E Chemes; Vassilios Papadopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-07       Impact factor: 11.205

2.  Effect of testicular morphology on embryo development to the blastocyst stage after round spermatid injection.

Authors:  Gokhun Ozmerdiven; Yavuz Guler; Eren Sahin; Zeynep Tatar; Akif Erbin; Ebubekir Dirican; Ahmet Hakan Haliloglu
Journal:  Am J Clin Exp Urol       Date:  2021-12-15

Review 3.  The Fate of Leydig Cells in Men with Spermatogenic Failure.

Authors:  Daria Adamczewska; Jolanta Słowikowska-Hilczer; Renata Walczak-Jędrzejowska
Journal:  Life (Basel)       Date:  2022-04-12

4.  Recombinant gonadotropin therapy to improve spermatogenesis in nonobstructive azoospermic patients - A proof of concept study.

Authors:  Rita Jakubcionyte Laursen; Birgit Alsbjerg; Helle Olesen Elbaek; Betina Boel Povlsen; Kirsten Brock Spanggaard Jensen; Jette Lykkegaard; Sandro C Esteves; Peter Humaidan
Journal:  Int Braz J Urol       Date:  2022 May-Jun       Impact factor: 3.050

5.  CircRNA expression profile and functional analysis in testicular tissue of patients with non-obstructive azoospermia.

Authors:  Pan Ge; Jian Zhang; Liang Zhou; Mo-Qi Lv; Yi-Xin Li; Jin Wang; Dang-Xia Zhou
Journal:  Reprod Biol Endocrinol       Date:  2019-11-27       Impact factor: 5.211

6.  microRNA-186 in extracellular vesicles from bone marrow mesenchymal stem cells alleviates idiopathic pulmonary fibrosis via interaction with SOX4 and DKK1.

Authors:  Jing Zhou; Yang Lin; Xiuhua Kang; Zhicheng Liu; Wei Zhang; Fei Xu
Journal:  Stem Cell Res Ther       Date:  2021-02-03       Impact factor: 6.832

7.  Islet transplantation ameliorates diabetes-induced testicular interstitial fibrosis and is associated with inhibition of TGF-β1/Smad2 pathway in a rat model of type 1 diabetes.

Authors:  Yuan-Cai Zheng; Yi-Ling Feng; Yi-Hong Wang; Li-Jun Kong; Ming-Shi Zhou; Min-Min Wu; Cheng-Yang Liu; Hua-Chun Weng; Hong-Wei Wang
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

8.  The expression of Beclin-1 in testicular tissues of non-obstructive azoospermia patients and its predictive value in sperm retrieval rate.

Authors:  Liang Zhou; Mo-Qi Lv; Pan Ge; Yan-Qi Yang; Da-Lin He; Hai-Xu Wang; Dang-Xia Zhou
Journal:  Transl Androl Urol       Date:  2021-08

9.  Does hormonal therapy improve sperm retrieval rates in men with non-obstructive azoospermia: a systematic review and meta-analysis.

Authors:  Tharu Tharakan; Giovanni Corona; Daniel Foran; Andrea Salonia; Nikolaos Sofikitis; Aleksander Giwercman; Csilla Krausz; Tet Yap; Channa N Jayasena; Suks Minhas
Journal:  Hum Reprod Update       Date:  2022-08-25       Impact factor: 17.179

10.  Spermatogenesis improved by suppressing the high level of endogenous gonadotropins in idiopathic non-obstructive azoospermia: a case control pilot study.

Authors:  Xuechun Hu; Zheng Ding; Zhiwei Hong; Zhichuan Zou; Yuming Feng; Ruilou Zhu; Jinzhao Ma; Xie Ge; Chaojun Li; Bing Yao
Journal:  Reprod Biol Endocrinol       Date:  2018-09-22       Impact factor: 5.211

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.